Vildagliptin / Metformin hydrochloride Accord Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - lieky používané pri cukrovke - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).

Vildagliptin/Metformin Sandoz 50 mg/1000 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vildagliptin/metformin sandoz 50 mg/1000 mg

sandoz pharmaceuticals d.d., slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Vildagliptin/Metformin Sandoz 50 mg/850 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vildagliptin/metformin sandoz 50 mg/850 mg

sandoz pharmaceuticals d.d., slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Vildagliptin/Metformin Teva 50 mg/1000 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vildagliptin/metformin teva 50 mg/1000 mg

teva b.v., holandsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Vildagliptin/Metformin Teva 50 mg/850 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vildagliptin/metformin teva 50 mg/850 mg

teva b.v., holandsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Eucreas Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Zomarist Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - lieky používané pri cukrovke - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.